Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra Inc. (NYSE: PEN) delivers innovative medical technologies transforming vascular intervention worldwide. This news hub provides investors and healthcare professionals with essential updates on the company's thrombectomy systems, regulatory milestones, and market strategies.
Access real-time press releases covering product approvals, clinical trial results, and financial performance. Our curated news collection includes analysis of Penumbra's neurovascular devices, partnership announcements, and global expansion initiatives.
Key updates feature developments in computer-assisted vacuum thrombectomy (CAVT) technology, peripheral vascular solutions, and quality improvement initiatives. Stay informed about Penumbra's progress in addressing ischemic stroke, pulmonary embolism, and other critical vascular conditions.
Bookmark this page for verified updates on Penumbra's operational achievements and industry leadership. Check regularly for insights into how the company's medical devices continue shaping modern interventional therapies across 100+ countries.
On April 25, 2023, Penumbra, Inc. (NYSE: PEN) announced its participation in two upcoming investor conferences:
- Bank of America Securities 2023 Health Care Conference
Date: May 9, 2023
Time: 1:40 PM ET / 10:40 AM PT - 2023 RBC Capital Markets Global Healthcare Conference
Date: May 16, 2023
Time: 11:30 AM ET / 8:30 AM PT
Webcasts of these presentations will be accessible on Penumbra's investor relations website for at least two weeks post-event. With its headquarters in Alameda, California, Penumbra focuses on innovative therapies and has a diverse product portfolio addressing substantial medical needs in over 100 countries.
Penumbra, Inc. (NYSE: PEN) has announced a conference call to discuss its financial results for the first quarter of 2023. The call is scheduled for May 2, 2023, at 4:30 PM Eastern Time, following the release of the financial results after market close. Investors can access the conference call by dialing (888) 330-2443 or via a live webcast on Penumbra's website. The company is focused on innovative therapies and operates in more than 100 countries, addressing significant unmet medical needs.
Penumbra has announced a three-year collaboration with the Veterans Health Administration (VHA) to develop and implement virtual reality solutions for rehabilitation. This partnership aims to enhance therapy accessibility, focusing on veterans' needs, including remote rehabilitation. The collaboration will utilize Penumbra's REAL y-Series platform, a hands-free, multi-disciplinary VR rehabilitation tool. The technology targets both neurorehabilitation and chronic condition management. The REAL system is already active in facilities nationwide, addressing various rehabilitation goals.
Penumbra, Inc. (NYSE: PEN) reported robust financial results for Q4 and the full year 2022. Q4 revenue reached $221.2 million, an 8.4% increase year-over-year, while total annual revenue for 2022 was $847.1 million, a 13.3% rise. US revenue grew to $157.1 million in Q4 and $591.7 million for the year. Gross profit for Q4 was $138.4 million, reflecting a gross margin of 62.6%. Penumbra anticipates 2023 revenue will exceed $1 billion, indicating at least 18% growth. The company showed strong vascular product sales, with a 14.2% increase in Q4.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
